Summit Therapeutics (SMMT) Return on Assets (2017 - 2025)
Historic Return on Assets for Summit Therapeutics (SMMT) over the last 8 years, with Q3 2025 value amounting to 0.22%.
- Summit Therapeutics' Return on Assets rose 100.0% to 0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 100.0%. This contributed to the annual value of 0.74% for FY2024, which is 6800.0% up from last year.
- Per Summit Therapeutics' latest filing, its Return on Assets stood at 0.22% for Q3 2025, which was up 100.0% from 0.36% recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Return on Assets registered a high of 0.08% during Q1 2023, and its lowest value of 0.36% during Q2 2025.
- For the 4-year period, Summit Therapeutics' Return on Assets averaged around 0.22%, with its median value being 0.22% (2025).
- Its Return on Assets has fluctuated over the past 5 years, first plummeted by -2200bps in 2024, then surged by 100bps in 2025.
- Quarter analysis of 4 years shows Summit Therapeutics' Return on Assets stood at 0.09% in 2022, then tumbled by -196bps to 0.27% in 2023, then dropped by 0bps to 0.27% in 2024, then rose by 17bps to 0.22% in 2025.
- Its Return on Assets was 0.22% in Q3 2025, compared to 0.36% in Q2 2025 and 0.31% in Q1 2025.